Metastasis News and Research RSS Feed - Metastasis News and Research

Metastasis is the spread of cancer from one part of the body to another. A tumor formed by cells that have spread is called a “metastatic tumor” or a “metastasis.” The metastatic tumor contains cells that are like those in the original (primary) tumor. The plural form of metastasis is metastases
Rice-led research shows how migratory cancer cells acquire 'stem-like' properties

Rice-led research shows how migratory cancer cells acquire 'stem-like' properties

In the first study of its kind, Rice University researchers have mapped how information flows through the genetic circuits that cause cancer cells to become metastatic. The research reveals a common pattern in the decision-making that allows cancer cells to both migrate and form new tumors. Researchers say the commonality may open the door to new drugs that interfere with the genetic switches that cancer must flip to form both cancer stem cells and circulating tumor cells -- two of the main players in cancer metastasis. [More]
Johns Hopkins engineers invent lab device that yields microscopic look at metastasis

Johns Hopkins engineers invent lab device that yields microscopic look at metastasis

Johns Hopkins engineers have invented a lab device to give cancer researchers an unprecedented microscopic look at metastasis, the complex way that tumor cells spread through the body, causing more than 90 percent of cancer-related deaths. By shedding light on precisely how tumor cells travel, the device could uncover new ways to keep cancer in check. [More]
TNF-α key player in RCC progression

TNF-α key player in RCC progression

Tumour necrosis factor - α appears to play a key role in the promotion of invasion and metastasis in clear cell renal cell carcinomas, Japanese study findings indicate. [More]
Adjuvant cisplatin for NSCLC raises non-cancer mortality risk

Adjuvant cisplatin for NSCLC raises non-cancer mortality risk

Re-analysis of data from the International Adjuvant Lung Cancer Trial indicates that cisplatin-based adjuvant chemotherapy increases the long-term risk of non-cancer mortality in patients with non-small-cell lung cancer. [More]
Study on papillary thyroid carcinoma to be presented at 84th Annual Meeting of the ATA

Study on papillary thyroid carcinoma to be presented at 84th Annual Meeting of the ATA

The prevalence of papillary thyroid carcinoma (PTC), the most common type of thyroid cancer, is increasing rapidly. New research to determine the impact of radioactive iodine (RAI) therapy on survival in PTC, describing a novel blood test able to detect circulating BRAFV600E-positive tumor DNA, and identifying a long non-coding RNA specifically associated with the thyroid that is down-regulated in PTC compared to normal thyroid tissue in patient-derived clinical specimens and cell cultures will be featured in oral presentations delivered at the 84th Annual Meeting of the American Thyroid Association, October 29-November 2, 2014, in Coronado, California. [More]
KU researchers find potential therapeutic target for triple-negative breast cancer

KU researchers find potential therapeutic target for triple-negative breast cancer

A team at the University of Kansas School of Medicine has identified a potential target for treating breast cancer, including a particularly deadly form of the disease. [More]
International Aspirin Foundation introduces two biennial awards

International Aspirin Foundation introduces two biennial awards

In celebration of the 40th anniversary of the formation of The International Aspirin Foundation, we are delighted to announce the introduction of two biennial awards; a Senior Science Award and a Young Investigator Award. [More]
Game theory and the cancer ecosystem: an interview with Professor Pienta, Johns Hopkins

Game theory and the cancer ecosystem: an interview with Professor Pienta, Johns Hopkins

The classic description of game theory was described by the prisoner's dilemma, which is a situation in which two players have two options where the outcome depends on the simultaneous choice made by the other. [More]
Ludwig researchers discover key mechanism that control plasticity of epithelial cells

Ludwig researchers discover key mechanism that control plasticity of epithelial cells

Ludwig Oxford researchers have discovered a key mechanism that governs how cells of the epithelia, the soft lining of inner body cavities, shift between a rigid, highly structured and immobile state and a flexible and motile form. [More]
Tiny nano-sized particles may play major role in detecting, tracking breast cancer

Tiny nano-sized particles may play major role in detecting, tracking breast cancer

Exosomes, tiny, virus-sized particles released by cancer cells, can bioengineer micro-RNA (miRNA) molecules resulting in tumor growth. They do so with the help of proteins, such as one named Dicer. New research from The University of Texas MD Anderson Cancer Center suggests Dicer may also serve as a biomarker for breast cancer and possibly open up new avenues for diagnosis and treatment. [More]
Anti-cancer nanomedicines with smaller sizes exhibit enhanced performance in vivo, show studies

Anti-cancer nanomedicines with smaller sizes exhibit enhanced performance in vivo, show studies

Nanomedicines consisting of nanoparticles for targeted drug delivery to specific tissues and cells offer new solutions for cancer diagnosis and therapy. [More]
Inflammation in tissue creates a niche for cancer cells

Inflammation in tissue creates a niche for cancer cells

In order to invade healthy tissue, tumor cells must leave the actual tumor and enter the bloodstream or lymphatic system. For this purpose, they use certain enzymes, proteases that break down the tissue surrounding the tumor, thus opening the way for tumor cells to reach blood or lymphatic vessels. To keep the proteases in check, the body produces inhibitors such as the protein TIMP-1, which thwart the proteases in their work. [More]
Blocking STAT3 in immune system cells increases anti-tumour immunity

Blocking STAT3 in immune system cells increases anti-tumour immunity

The STAT transcription factors are involved in the development of many forms of cancer. STAT3 is frequently activated in tumour cells, so drugs targeting STAT3 could be used in cancer therapy. However, STAT3 is also important in the development of the immune system. Dagmar Gotthardt and colleagues at the Vetmeduni Vienna now show that blocking STAT3 in cells of the immune system actually leads to increased anti-tumour immunity. Anti-STAT3 therapy may thus be highly promising. [More]
BCRF announces $58.6 million commitment to breast cancer research

BCRF announces $58.6 million commitment to breast cancer research

The Breast Cancer Research Foundation, announced its dedication of $58.6 million to breast cancer research today at its annual Symposium & Awards Luncheon. Totaling $47 million, the 2014-2015 annual grants, awarded to more than 220 physicians and scientists on six continents, continue to fuel BCRF's mission of advancing the world's most innovative research. [More]
GenomOncology, med fusion partner to optimize treatment strategies for tumor

GenomOncology, med fusion partner to optimize treatment strategies for tumor

med fusion, an integrated molecular center of excellence and clinical trials service organization and GenomOncology, an Ohio based genomics technology and services provider, today announced a partnership to optimize treatment strategies based on the patient's disease state and tumor profile. [More]

Researchers discover novel mechanisms of cell migration

During cancer metastasis, immune response or the development of organisms, cells are moving in a controlled manner through the body. Researchers from the Department of Biomedicine at the University of Basel discovered novel mechanisms of cell migration by observing cells moving on lines of connective tissue. [More]

Delta Air Lines kicks off annual campaign to promote awareness on breast cancer

Delta Air Lines' (NYSE: DAL) annual "Breast Cancer One" employee survivor flight took place yesterday, kicking off the airline's month-long campaign to generate awareness and raise money for The Breast Cancer Research Foundation. [More]
Trastuzumab offers better outcome than lapatinib for HER2-positive breast cancer patients

Trastuzumab offers better outcome than lapatinib for HER2-positive breast cancer patients

Analysis of more than 8,000 women who participated in the world's largest study of two treatments for HER2-positive breast cancer reinforces other findings from the clinical trial showing that trastuzumab (Herceptin) should remain the standard of care for this cancer, says a Mayo Clinic researcher. [More]
ANN expands commitment to BCRF through annual Breast Cancer Awareness campaign

ANN expands commitment to BCRF through annual Breast Cancer Awareness campaign

ANN INC., the parent Company of Ann Taylor and LOFT, today announces its expanded commitment to The Breast Cancer Research Foundation through its annual Breast Cancer Awareness campaign and latest in-store and online promotions. [More]
Alectinib promise for crizotinib-resistant NSCLC

Alectinib promise for crizotinib-resistant NSCLC

Alectinib has shown promising antitumour activity in patients with ALK-rearranged non-small-cell lung cancer that is resistant to crizotinib, researchers report. [More]